EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

A quest for stakeholder synchronization in the CAR T-cell therapy supply chain

Shelby M Holland, Amrik Sohal, Alka Ashwini Nand, Dietmar W Hutmacher

Frontiers in Bioengineering and Biotechnology · 08.08.2024 · 12

DOI: 10.3389/fbioe.2024.1413688 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Bioengineering and Biotechnology, online erschienen am 08.08.2024. Verfasst von Shelby M Holland und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Management, Monash Business School, Monash University Caufield Campus, Melbourne, VIC, Australia. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advancements in cell therapy have the potential to improve healthcare accessibility for eligible patients. However, there are still challenges in scaling production and reducing costs. These challenges involve various stakeholders such as the manufacturing facility, third-party logistics (3PL) company, and medical center. Proposed solutions tend to focus on individual companies rather than addressing the interconnectedness of the supply chain’s challenges. The challenges can be categorized as barriers from product characteristics, regulatory requirements, or lagging infrastructure. Each barrier affects multiple stakeholders, especially during a boundary event like product handover. Therefore, solutions that only consider the objectives of one stakeholder fail to address underlying problems. This review examines the interconnecting cell therapy supply chain challenges and how they affect the multiple stakeholders involved. The authors consider whether proposed solutions impact individual stakeholders or the entire supply chain and discuss the benefits of stakeholder coordination-focused solutions such as integrated technologies and information tracking. The review highlights how coordination efforts allow for the implementation of widely-supported cell therapy supply solutions such as decentralized manufacturing through stakeholder collaboration.

Schlagwörter

Stichwörter der Autor:innen

car-tcell therapycold-chain managementcollaborationlogisticsstakeholder coordinationsupply chain

Autor:innen und Institutionen

  • Department of Management, Monash Business School, Monash University Caufield Campus, Melbourne, VIC, Australia.
  • Australian Research Council Training Centre for Cell and Tissue Engineering Technologies, Monash University Clayton Campus, Melbourne, VIC, Australia.
  • Faculty of Engineering, School of Mechanical Medical and Process Engineering, Queensland University of Technology, Brisbane, QLD, Australia.
  • Australian Research Council Training Centre for Multiscale 3D Imaging, Modelling and Manufacturing (M3D Innovation), Queensland University of Technology, Kelvin Grove, QLD, Australia.
  • Max Planck Queensland Centre, Queensland University of Technology, Brisbane, QLD, Australia.

Förderung

  • Australian Research Council

Zitieren

APA

Holland, S. M., Sohal, A., Nand, A. A., & Hutmacher, D. W. (2024). A quest for stakeholder synchronization in the CAR T-cell therapy supply chain. Frontiers in Bioengineering and Biotechnology, 12. https://doi.org/10.3389/fbioe.2024.1413688

Vancouver

Holland SM, Sohal A, Nand AA, Hutmacher DW. A quest for stakeholder synchronization in the CAR T-cell therapy supply chain. Frontiers in Bioengineering and Biotechnology. 2024;12. doi:10.3389/fbioe.2024.1413688

BibTeX
@article{Holland2024,
  author = {Holland, Shelby M and Sohal, Amrik and Nand, Alka Ashwini and Hutmacher, Dietmar W},
  title = {A quest for stakeholder synchronization in the CAR T-cell therapy supply chain},
  journal = {Frontiers in Bioengineering and Biotechnology},
  year = {2024},
  volume = {12},
  doi = {10.3389/fbioe.2024.1413688}
}
Kostenlos starten →